COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,550 Articles (22,881 medRxiv, 8,669 bioRxiv)

Most recent first Previous |  Page 1023: Articles 10221-10230  | Next

Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study
Suah, J. L., Husin, M., Tok, P. S. K., Tng, B. H., Thevananthan, T., Low, E. V., Appannan, M. R., Muhamad Zin, F., Mohd Zin, S., Yahaya, H., Peariasamy, K. M., Sivasampu, S.
10.1101/2022.01.15.22269326 — Posted: 2022-01-16
Resilient T cell responses to B.1.1.529 (Omicron) SARS-CoV-2 variant
Jergovic, M., Coplen, C. P., Uhrlaub, J. L., Beitel, S. C., Burgess, J. L., Lutrick, K., Ellingson, K. D., Watanabe, M., Nikolich-Zugich, J.
10.1101/2022.01.16.22269361 — Posted: 2022-01-16
A prospective, single-center study to evaluate the clinical performance of Meril ABFind in individuals vaccinated against COVID-19
Shastri, J., Agrawal, S., Chatterjee, N., Gupta, H.
10.1101/2022.01.15.22269231 — Posted: 2022-01-16
Development of an effective immune response in adults with Down Syndrome after SARS-CoV-2 vaccination
Esparcia-Pinedo, L., Yarci-Carrion, A., Mateo-Jimenez, G., Ropero, N., Gomez-Cabanas, L., Lancho-Sanchez, A., Martin-Gayo, E., Sanchez-Madrid, F., Moldenhauer, F., Gutierrez-Cobos, A., Real de Asua, D., Alfranca, A.
10.1101/2022.01.14.22269303 — Posted: 2022-01-16
Waning Effectiveness of SARS-CoV-2 mRNA Vaccines in Older Adults: A Rapid Review
Nanishi, E., Levy, O., Ozonoff, A.
10.1101/2022.01.15.22269364 — Posted: 2022-01-16
Distinct Vaccine Efficacy Rates Among Health Care Workers During a COVID-19 Outbreak in Jordan
Sultan, I., Tbakhi, A., Abuatta, O., Mubarak, S., Alsmadi, O., Edilbi, A., Al-Ani, R., Makhlouf, M., Hajir, R., Khresat, O., Al Ruzeieh, M. A., Abdelrazeq, H., Mansour, A.
10.1101/2022.01.15.22269356 — Posted: 2022-01-16
Forecast of omicron wave time evolution
Schlickeiser, R., Kroger, M.
10.1101/2022.01.16.22269161 — Posted: 2022-01-16
Background incidence rates of adverse events of special interest related to COVID-19 vaccines in Ontario, Canada, 2015 to 2020, to inform COVID-19 vaccine safety surveillance
Nasreen, S., Calzavara, A., Buchan, S. A., Thampi, N., Johnson, C., Wilson, S. E., Kwong, J. C.
10.1101/2022.01.12.22269169 — Posted: 2022-01-16
Using Mobile Phone-based Text Message to Recruit Representative Samples: Assessment of a Cross-Sectional Survey about the COVID-19 Vaccine Hesitation.
Sartorao Filho, C. I., Sartorao Neto, C. I., Sartorao, A. L. V., Terribile, D. C., Mello, B. B. d., Mello, R., Zoqui, M. C., Duarte, D. O., Bisseto, V. C. Q., Ribeiro, E. A. C., Cachoni, L. E. G.
10.1101/2022.01.15.22269259 — Posted: 2022-01-16
Generation of novel SARS-CoV-2 variants on B.1.1.7 lineage in three patients with advanced HIV disease
Riddell, A. C., Kele, B., Harris, K., Bible, J., Murphy, M., Dakshina, S., Storey, N., Owoyemi, D., Pade, C., Gibbons, J. M., Harrington, D., Alexander, E., McKnight, A., Cutino-Moguel, T.
10.1101/2022.01.14.21267836 — Posted: 2022-01-15

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).